Abstract
During the past decade, both in vitro and in vivo studies have provided new insights into the cellular and molecular mechanisms that govern angiogenesis and arteriogenesis. However, therapeutic angiogenesis clinical trials using recombinant protein or gene therapy formulations of single angiogenic growth factors have yielded at best only modest success to date. Among the second generation of angiogenic agents are therapeutic transgenes that enhance expression of two or more proangiogenic cytokines. These include synthetic constructs that mimic that activity of endogenous transcriptional regulators and other upstream, regulatory factors that have the potential to induce formation of morphologically and physiologically functional vessels. These agents are now beginning to be evaluated in clinical trials for patients with advanced ischemic cardiac and peripheral vascular disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kipshidze NN, Tsapenko MV, Leon MB, Stone GW, Moses JW . Update on drug-eluting coronary stents. Expert Rev Cardiovasc Ther 2005; 3: 953–968.
Stettler C, Allemann S, Egger M, Windecker S, Meier B, Diem P . Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials. Heart 2006; 92: 650–657.
Salam AM, Al Suwaidi J, Holmes Jr DR . Drug-eluting coronary stents. Curr Probl Cardiol 2006; 31: 8–119.
Arora R, Sowers JR, Saunders E, Probstfield J, Lazar HL . Cardioprotective strategies to improve long-term outcomes following coronary artery bypass surgery. J Card Surg 2006; 21: 198–204.
Likosky DS, Nugent WC, Ross CS . Improving outcomes of cardiac surgery through cooperative efforts: the northern New England experience. Semin Cardiothorac Vasc Anesth 2005; 9: 119–121.
Serruys PW, Sianos G, Abizaid A, Aoki J, den Heijer P, Bonnier H et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 2005; 46: 253–260.
Colombo A, Cosgrave J . Paclitaxel-eluting stents in complex lesions. JAMA 2005; 294: 1268–1270.
Klein LW . Are drug-eluting stents the preferred treatment for multivessel coronary artery disease? J Am Coll Cardiol 2006; 47: 22–26.
Aronow WS . Management of peripheral arterial disease. Cardiol Rev 2005; 13: 61–68.
Wann-Hansson C, Hallberg IR, Risberg B, Lundell A, Klevsgard R . Health-related quality of life after revascularization for peripheral arterial occlusive disease: long-term follow-up. J Adv Nurs 2005; 51: 227–235.
Simons M . Angiogenesis: where do we stand now? Circulation 2005; 111: 1556–1566.
Carmeliet P . Angiogenesis in life, disease and medicine. Nature 2005; 438: 932–936.
Papayannopoulou T . Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization. Blood 2004; 103: 1580–1585.
Asahara T, Kawamoto A . Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol 2004; 287: C572–C579.
Armulik A, Abramsson A, Betsholtz C . Endothelial/pericyte interactions. Circ Res 2005; 97: 512–523.
Rundhaug JE . Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005; 9: 267–285.
Yu J, deMuinck ED, Zhuang Z, Drinane M, Kauser K, Rubanyi GM et al. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci USA 2005; 102: 10999–11004.
Hagedorn M, Balke M, Schmidt A, Bloch W, Kurz H, Javerzat S et al. VEGF coordinates interaction of pericytes and endothelial cells during vasculogenesis and experimental angiogenesis. Dev Dyn 2004; 230: 23–33.
Lehti K, Allen E, Birkedal-Hansen H, Holmbeck K, Miyake Y, Chun TH et al. An MT1-MMP-PDGF receptor-beta axis regulates mural cell investment of the microvasculature. Genes Dev 2005; 19: 979–991.
Heil M, Schaper W . Influence of mechanical, cellular, and molecular factors on collateral artery growth (arteriogenesis). Circ Res 2004; 95: 449–458.
Ho TK, Rajkumar V, Ponticos M, Leoni P, Black DC, Abraham DJ et al. Increased endogenous angiogenic response and hypoxia-inducible factor-1alpha in human critical limb ischemia. J Vasc Surg 2006; 43: 125–133.
Shirakawa Y, Sawa Y, Takewa Y, Tatsumi E, Kaneda Y, Taenaka Y et al. Gene transfection with human hepatocyte growth factor complementary DNA plasmids attenuates cardiac remodeling after acute myocardial infarction in goat hearts implanted with ventricular assist devices. J Thorac Cardiovasc Surg 2005; 130: 624–632.
Cao R, Eriksson A, Kubo H, Alitalo K, Cao Y, Thyberg J . Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res 2004; 94: 664–670.
Ferrara N, Kerbel RS . Angiogenesis as a therapeutic target. Nature 2005; 438: 967–974.
Vincent KA, Kelly RA . Integrative Pro-Angiogenic Activation Therapeutic Neovascularization. Springer Life Sciences: New York, NY, USA, 2006.
Annex BH, Simons M . Growth factor-induced therapeutic angiogenesis in the heart: protein therapy. Cardiovasc Res 2005; 65: 649–655.
Frantz S, Vincent KA, Feron O, Kelly RA . Innate immunity and angiogenesis. Circ Res 2005; 96: 15–26.
Kastrup J, Jorgensen E, Ruck A, Tagil K, Glogar D, Ruzyllo W et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 2005; 45: 982–988.
Lekas M, Lekas P, Latter DA, Kutryk MB, Stewart DJ . Growth factor-induced therapeutic neovascularization for ischaemic vascular disease: time for a re-evaluation? Curr Opin Cardiol 2006; 21: 376–384.
Tirziu D, Simons M . Angiogenesis in the human heart: gene and cell therapy. Angiogenesis 2005; 8: 241–251.
Gounis MJ, Spiga MG, Graham RM, Wilson A, Haliko S, Lieber BB et al. Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle. Gene Therapy 2005; 12: 762–771.
Zheng Y, Murakami M, Takahashi H, Yamauchi M, Kiba A, Yamaguchi S et al. Chimeric VEGF-E(NZ7)/PlGF promotes angiogenesis via VEGFR-2 without significant enhancement of vascular permeability and inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 2019–2026.
Morishita R, Aoki M, Hashiya N, Makino H, Yamasaki K, Azuma J et al. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 2004; 44: 203–209.
Nikol S, Murphy SA, Gibson CM . Therapeutic angiogenesis with intramuscular NV1FGF in patients with critical limb ischemia. Am Coll Cardiol 2006, Abstract.
Semenza GL . Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda) 2004; 19: 176–182.
Lahiri S, Roy A, Baby SM, Hoshi T, Semenza GL, Prabhakar NR . Oxygen sensing in the body. Prog Biophys Mol Biol 2006; 91: 249–286.
Schofield CJ, Ratcliffe PJ . Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004; 5: 343–354.
Trentin D, Hall H, Wechsler S, Hubbell JA . Peptide-matrix-mediated gene transfer of an oxygen-insensitive hypoxia-inducible factor-1alpha variant for local induction of angiogenesis. Proc Natl Acad Sci USA 2006; 103: 2506–2511.
Patel TH, Kimura H, Weiss CR, Semenza GL, Hofmann LV . Constitutively active HIF-1alpha improves perfusion and arterial remodeling in an endovascular model of limb ischemia. Cardiovasc Res 2005; 68: 144–154.
Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858–864.
Ceradini DJ, Gurtner GC . Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc Med 2005; 15: 57–63.
Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A, Belperio JA et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 2005; 280: 22473–22481.
Hirota K, Semenza GL . Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 2006; 59: 15–26.
Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006; 124: 175–189.
Pajusola K, Kunnapuu J, Vuorikoski S, Soronen J, Andre H, Pereira T et al. Stabilized HIF-1alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer. FASEB J 2005; 19: 1365–1367.
Heinl-Green A, Radke PW, Munkonge FM, Frass O, Zhu J, Vincent K et al. The efficacy of a ‘master switch gene’ HIF-1alpha in a porcine model of chronic myocardial ischaemia. Eur Heart J 2005; 26: 1327–1332.
Luo Y, Jiang C, Belanger AJ, Akita GY, Wadsworth SC, Gregory RJ et al. Constitutively active hypoxia-inducible factor-1alpha/VP16 hybrid factor activates expression of the human B-type natriuretic peptide gene. Mol Pharmacol 2006; 69: 1953–1962.
Wilhide ME, Jones WK . Potential therapeutic gene for the treatment of ischemic disease: Ad2/hypoxia-inducible factor-1alpha (HIF-1)/VP16 enhances B-type natriuretic peptide gene expression via a HIF-1-responsive element. Mol Pharmacol 2006; 69: 1773–1778.
Kido M, Du L, Sullivan CC, Li X, Deutsch R, Jamieson SW et al. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol 2005; 46: 2116–2124.
Date T, Mochizuki S, Belanger AJ, Yamakawa M, Luo Z, Vincent KA et al. Expression of constitutively stable hybrid hypoxia-inducible factor-1alpha protects cultured rat cardiomyocytes against simulated ischemia–reperfusion injury. Am J Physiol Cell Physiol 2005; 288: C314–C320.
Natarajan R, Salloum FN, Fisher BJ, Kukreja RC, Fowler III AA . Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Circ Res 2006; 98: 133–140.
Siddiq A, Ayoub IA, Chavez JC, Aminova L, Shah S, LaManna JC et al. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem 2005; 280: 41732–41743.
Baek JH, Mahon PC, Oh J, Kelly B, Krishnamachary B, Pearson M et al. OS-9 interacts with hypoxia-inducible factor 1alpha and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1alpha. Mol Cell 2005; 17: 503–512.
Flashman E, McDonough MA, Schofield CJ . OS-9: another piece in the HIF complex story. Mol Cell 2005; 17: 472–473.
Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, Gleadle JM . Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem 2006; 281: 15215–15226.
Diaz-Gonzalez JA, Russell J, Rouzaut A, Gil-Bazo I, Montuenga L . Targeting hypoxia and angiogenesis through HIF-1alpha inhibition. Cancer Biol Ther 2005; 4: 1055–1062.
Safran M, Kim WY, O'Connell F, Flippin L, Gunzler V, Horner JW et al. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci USA 2006; 103: 105–110.
Huang Y, Hickey RP, Yeh JL, Liu D, Dadak A, Young LH et al. Cardiac myocyte-specific HIF-1alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart. FASEB J 2004; 18: 1138–1140.
Kim JW, Tchernyshyov I, Semenza GL, Dang CV . HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3: 177–185.
Takeda N, Maemura K, Imai Y, Harada T, Kawanami D, Nojiri T et al. Endothelial PAS domain protein 1 gene promotes angiogenesis through the transactivation of both vascular endothelial growth factor and its receptor, Flt-1. Circ Res 2004; 95: 146–153.
Walmsley SR, Cadwallader KA, Chilvers ER . The role of HIF-1alpha in myeloid cell inflammation. Trends Immunol 2005; 26: 434–439.
Zarember KA, Malech HL . HIF-1alpha: a master regulator of innate host defenses? J Clin Invest 2005; 115: 1702–1704.
Hellwig-Burgel T, Stiehl DP, Wagner AE, Metzen E, Jelkmann W . Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. J Interferon Cytokine Res 2005; 25: 297–310.
Peyssonnaux C, Datta V, Cramer T, Doedens A, Theodorakis EA, Gallo RL et al. HIF-1alpha expression regulates the bactericidal capacity of phagocytes. J Clin Invest 2005; 115: 1806–1815.
Heil M, Eitenmuller I, Schmitz-Rixen T, Schaper W . Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med 2006; 10: 45–55.
Eitenmuller I, Volger O, Kluge A, Troidl K, Barancik M, Cai WJ et al. The range of adaptation by collateral vessels after femoral artery occlusion. Circ Res 2006; 99: 656–662.
Oda T, Hirota K, Nishi K, Takabuchi S, Oda S, Yamada H et al. Activation of hypoxia-inducible factor 1 during macrophage differentiation. Am J Physiol Cell Physiol 2006; 291: C104–C113.
Kempf VA, Lebiedziejewski M, Alitalo K, Walzlein JH, Ehehalt U, Fiebig J et al. Activation of hypoxia-inducible factor-1 in bacillary angiomatosis: evidence for a role of hypoxia-inducible factor-1 in bacterial infections. Circulation 2005; 111: 1054–1062.
Zhang W, Petrovic JM, Callaghan D, Jones A, Cui H, Howlett C et al. Evidence that hypoxia-inducible factor-1 (HIF-1) mediates transcriptional activation of interleukin-1beta (IL-1beta) in astrocyte cultures. J Neuroimmunol 2006; 174: 63–73.
Louis NA, Hamilton KE, Kong T, Colgan SP . HIF-dependent induction of apical CD55 coordinates epithelial clearance of neutrophils. FASEB J 2005; 19: 950–959.
Neumann AK, Yang J, Biju MP, Joseph SK, Johnson RS, Haase VH et al. Hypoxia inducible factor 1 alpha regulates T cell receptor signal transduction. Proc Natl Acad Sci USA 2005; 102: 17071–17076.
Althaus J, Bernaudin M, Petit E, Toutain J, Touzani O, Rami A . Expression of the gene encoding the pro-apoptotic BNIP3 protein and stimulation of hypoxia-inducible factor-1alpha (HIF-1alpha) protein following focal cerebral ischemia in rats. Neurochem Int 2006; 48: 687–695.
van Royen N, Schirmer SH, Atasever B, Behrens CY, Ubbink D, Buschmann EE et al. START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte–macrophage colony-stimulating factor as a new treatment for peripheral vascular disease. Circulation 2005; 112: 1040–1046.
Post MJ, Sato K, Murakami M, Bao J, Tirziu D, Pearlman JD et al. Adenoviral PR39 improves blood flow and myocardial function in a pig model of chronic myocardial ischemia by enhancing collateral formation. Am J Physiol Regul Integr Comp Physiol 2006; 290: R494–R500.
Muinck ED, Nagy N, Tirziu D, Murakami M, Gurusamy N, Boswami SK et al. Protection against myocardial ischemia–reperfusion injury by the angiogenic masterswitch protein PR39 gene therapy: the roles of HIF-1alpha stabilization and FGFR1 signaling. Antioxid Redox Signal 2007; 9: 437–445.
Wu J, Parungo C, Wu G, Kang PM, Laham RJ, Sellke FW et al. PR39 inhibits apoptosis in hypoxic endothelial cells: role of inhibitor apoptosis protein-2. Circulation 2004; 109: 1660–1667.
Shie JL, Wu G, Wu J, Liu FF, Laham RJ, Oettgen P et al. RTEF-1, a novel transcriptional stimulator of vascular endothelial growth factor in hypoxic endothelial cells. J Biol Chem 2004; 279: 25010–25016.
Mizukami Y, Fujiki K, Duerr EM, Gala M, Jo WS, Zhang X et al. Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J Biol Chem 2006; 281: 13957–13963.
Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005; 9: 617–628.
Sainson RC, Harris AL . Hypoxia-regulated differentiation: let's step it up a Notch. Trends Mol Med 2006; 12: 141–143.
Hilfiker-Kleiner D, Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer G et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 2004; 95: 187–195.
Ingley E, Klinken SP . Cross-regulation of JAK and Src kinases. Growth Factors 2006; 24: 89–95.
Hilfiker-Kleiner D, Limbourg A, Drexler H . STAT3-mediated activation of myocardial capillary growth. Trends Cardiovasc Med 2005; 15: 152–157.
Hilfiker-Kleiner D, Hilfiker A, Kaminski K, Schaefer A, Park JK, Michel K et al. Lack of JunD promotes pressure overload-induced apoptosis, hypertrophic growth, and angiogenesis in the heart. Circulation 2005; 112: 1470–1477.
Bhattacharya S, Macdonald ST, Farthing CR . Molecular mechanisms controlling the coupled development of myocardium and coronary vasculature. Clin Sci (Lond) 2006; 111: 35–46.
Gommans WM, Haisma HJ, Rots MG . Engineering zinc finger protein transcription factors: the therapeutic relevance of switching endogenous gene expression on or off at command. J Mol Biol 2005; 354: 507–519.
Yu J, Lei L, Hinh L, Hickey RP, Huang Y, Liu D et al. An engineered VEGF-activating zinc finger protein transcription factor improves blood flow and limb salvage in advanced-age mice. FASEB J 2006; 20: 479–481.
Dai Q, Huang J, Klitzman B, Dong C, Goldschmidt-Clermont PJ, March KL et al. Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia. Circulation 2004; 110: 2467–2475.
Xie D, Li Y, Reed EA, Odronic SI, Kontos CD, Annex BH . An engineered vascular endothelial growth factor-activating transcription factor induces therapeutic angiogenesis in ApoE knockout mice with hindlimb ischemia. J Vasc Surg 2006; 44: 166–175.
Lucerna M, Pomyje J, Mechtcheriakova D, Kadl A, Gruber F, Bilban M et al. Sustained expression of early growth response protein-1 blocks angiogenesis and tumor growth. Cancer Res 2006; 66: 6708–6713.
Khachigian LM . Early growth response-1 in cardiovascular pathobiology. Circ Res 2006; 98: 186–191.
Worden B, Yang XP, Lee TL, Bagain L, Yeh NT, Cohen JG et al. Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma. Cancer Res 2005; 65: 7071–7080.
Heil M, Schaper W . Arteriogenic growth factors, chemokines and proteases as a prerequisite for arteriogenesis. Drug News Perspect 2005; 18: 317–322.
Schalch P, Patejunas G, Retuerto M, Sarateanu S, Milbrandt J, Thakker G et al. Homozygous deletion of early growth response 1 gene and critical limb ischemia after vascular ligation in mice: evidence for a central role in vascular homeostasis. J Thorac Cardiovasc Surg 2004; 128: 595–601.
Stamatovic SM, Dimitrijevic OB, Keep RF, Andjelkovic AV . Inflammation and brain edema: new insights into the role of chemokines and their receptors. Acta Neurochir Suppl 2006; 96: 444–450.
Hashiya N, Jo N, Aoki M, Matsumoto K, Nakamura T, Sato Y et al. In vivo evidence of angiogenesis induced by transcription factor Ets-1: Ets-1 is located upstream of angiogenesis cascade. Circulation 2004; 109: 3035–3041.
Martin P, Parkhurst SM . Parallels between tissue repair and embryo morphogenesis. Development 2004; 131: 3021–3034.
Mace KA, Hansen SL, Myers C, Young DM, Boudreau N . HOXA3 induces cell migration in endothelial and epithelial cells promoting angiogenesis and wound repair. J Cell Sci 2005; 118: 2567–2577.
Matsuki A, Yamamoto S, Nakagami H, Aoki M, Tamai K, Matsumoto K et al. No influence of tumor growth by intramuscular injection of hepatocyte growth factor plasmid DNA: safety evaluation of therapeutic angiogenesis gene therapy in mice. Biochem Biophys Res Commun 2004; 315: 59–65.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vincent, K., Jiang, C., Boltje, I. et al. Gene therapy progress and prospects: therapeutic angiogenesis for ischemic cardiovascular disease. Gene Ther 14, 781–789 (2007). https://doi.org/10.1038/sj.gt.3302953
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302953
Keywords
This article is cited by
-
Prospects for gene transfer for clinical heart failure
Gene Therapy (2012)
-
Intradermal Delivery of Plasmid VEGF165 by Electroporation Promotes Wound Healing
Molecular Therapy (2009)
-
VEGF Gene Therapy Fails to Improve Perfusion of Ischemic Myocardium in Patients With Advanced Coronary Disease: Results of the NORTHERN Trial
Molecular Therapy (2009)
-
Local and Sustained Vascular Endothelial Growth Factor Delivery for Angiogenesis Using an Injectable System
Pharmaceutical Research (2009)